Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00506805 | Safety And Pharmacology Study Of SNX-5422 Mesylate In Subjects With Refractory Solid Tumor Malignancies | PHASE1 | COMPLETED | 44 | — | — | Jun 1, 2007 | Mar 1, 2010 | May 28, 2012 | 2 | United States |
| Arm | Type | Description |
|---|---|---|
| Single Arm | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| SNX-5422 | DRUG | dose escalated, tablets every other day; undetermined duration until disease progression |
Inclusion Criteria: * \>18 years old * histologically confirmed solid tumor malignancy * refractory to available therapy or for which no therapy is available * adequate organ function Exclusion Criteria: * CNS malignancy * significant GI disease * at risk for prolonged QT interval
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GE Healthcare Technologies Inc. | GEHC | 1 | PHASE1 | GEH200520 / GEH200521 - Part A |
| Zimmer Biomet Holdings, Inc. | ZBH | 1 | — | Undisclosed |
| Ascentage Pharma Group International Unsponsored ADR | AAPG | 1 | PHASE1 | Olverembatinib |